Journal: British Journal of Cancer

Article Title: The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma

doi: 10.1038/s41416-019-0471-0

Figure Lengend Snippet: Cdc20 mRNA expression is increased in DLBCL and MCL patients and is associated with worse survival in DLBCL patients. a , b Cdc20 and Cdh1 mRNA expression in DLBCL. Cdc20 ( a ) and Cdh1 ( b ) gene expression levels of B-cell samples ( n = 33), patients with ABC–DLBCL ( n = 190), patients with GCB–DLBCL ( n = 212) and patients with unclassified DLBCL ( n = 67) were obtained from the publicly available microarray datasets GSE10846 and GSE56315. Mean expression±SD is shown in red. ** p < 0.01 and *** p < 0.001. c , d Cdc20 and Cdh1 mRNA expression in indolent and aggressive MCL. Cdc20 ( c ) and Cdh1 ( d ) gene expression levels of patients with indolent ( n = 7) and aggressive MCL ( n = 15) were obtained from the GSE16455 dataset. Mean expression ± SD is shown in red. * p < 0.05. e , f Prognostic value of Cdc20 and Cdh1 mRNA levels in terms of overall survival in DLBCL. The prognostic value of Cdc20 ( e ) and Cdh1 ( f ) was determined in DLBCL patients receiving R-CHOP treatment from the Lenz cohort ( n = 233) using Maxstat analysis (cut-off value used for Cdc20 is 11.679 and for Cdh1 8.319). Data were analysed through genomicscape ( http://genomicscape.com ). g – j Immunohistochemical analysis of Cdc20 expression in primary DLBCL patient samples. Immunohistochemical analysis of Cdc20 expression in a DLBCL patient. A ×4 and ×40 magnification is shown ( g ). Percentage of Cdc20-positive lymphoma cells was counted in 34 DLBCL patients and plotted against the estimated prognosis according to the R-IPI score of the patients ( h ). Percentage of Cdc20-positive cells was also plotted against the molecular subtype ( i ) and double-expresser status ( j ) in 27 DLBCL patients

Article Snippet: All samples were stained with Cdc20 antibody (ATLAS Antibodies AB, Bromma, Sweden) using an automated immunostainer Benchmark XT (Roche Ventana, Basel, Switzerland).

Techniques: Expressing, Gene Expression, Microarray, Immunohistochemical staining

Journal: British Journal of Cancer

Article Title: The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma

doi: 10.1038/s41416-019-0471-0

Figure Lengend Snippet: COX univariate and multivariate analysis of overall survival in R-CHOP-treated DLBCL ( n = 233) including Cdc20 gene expression

Article Snippet: All samples were stained with Cdc20 antibody (ATLAS Antibodies AB, Bromma, Sweden) using an automated immunostainer Benchmark XT (Roche Ventana, Basel, Switzerland).

Techniques:

Journal: British Journal of Cancer

Article Title: The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma

doi: 10.1038/s41416-019-0471-0

Figure Lengend Snippet: Pharmacological inhibition of the APC/C with proTAME results in a metaphase arrest. a Effect of proTAME treatment on the substrates of the APC/C co-activators Cdc20 and Cdh1. Expression of cyclin B1 and Skp2 was determined at different timepoints in the MCL and DLBCL cell lines after synchronisation and release into proTAME treatment (3 µM in SU-DHL-6 and 6 µM in Jeko-1 and U2932). APC3 and β-actin were used as indicators of mitotic arrest and loading control. Arrows show the phosphorylated APC3. One experiment representative of three is shown (the results shown are from the same experiment as those shown in Fig. ). Normalisation was performed with Image J and quantification relative to the M condition is shown. Bars represent the mean± SD of three independent experiments. b , c Effect of proTAME treatment on cell cycle progression. The effect on cell cycle progression was determined using PI staining on cell lines treated with 3 µM (SU-DHL-6) or 6 µM (Jeko-1 and U2932) proTAME for the indicated timepoints after synchronisation ( b ). To further examine the effect on mitosis, cytospins of these treated cells were stained with May–Grünwald Giemsa. For each sample, 3 × 100 cells were counted per cytospin. Quantification of the percentage of cells in the metaphase is shown ( c ). The results shown in each graph are the mean ± SD of three independent experiments. * p < 0.05 and ** p < 0.01. M = mitosis, −4 = 4 h before mitosis, −2 = 2 h before mitosis, +3 = 3 h after mitosis and +6 = 6 h after mitosis

Article Snippet: All samples were stained with Cdc20 antibody (ATLAS Antibodies AB, Bromma, Sweden) using an automated immunostainer Benchmark XT (Roche Ventana, Basel, Switzerland).

Techniques: Inhibition, Expressing, Control, Staining

Journal: British Journal of Cancer

Article Title: The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma

doi: 10.1038/s41416-019-0471-0

Figure Lengend Snippet: APC/C inhibition enhances the anti-lymphoma activity of the Cdc20/Cdh1 inhibitor apcin and the clinically relevant agent doxorubicin. a–c The anti-lymphoma effect of APC/C targeting in combination with apcin, doxorubicin or rituximab. Apoptosis of proTAME (pT) and/or apcin ( a ), doxorubicin ( b ) or rituximab ( c ) treated with Jeko-1, SU-DHL-6 and U2932 cells was determined after 48 h using Annexin V/7′-AAD staining followed by flow-cytometric analysis. The sum of the percentage of Annexin V and Annexin V/7′-AAD-positive cells are shown. The results shown in each graph are the mean ± SD of four independent experiments. * p < 0.05, ** p < 0.01 and *** p < 0.001 when compared with both single agents. Combination index (CI) values were calculated for the different drug concentrations by the Chou and Thalalay method using CompuSyn 1.0 software (nd: not determined, CI ≤ 1: synergistic)

Article Snippet: All samples were stained with Cdc20 antibody (ATLAS Antibodies AB, Bromma, Sweden) using an automated immunostainer Benchmark XT (Roche Ventana, Basel, Switzerland).

Techniques: Inhibition, Activity Assay, Staining, Software

Journal: Journal of Clinical & Translational Endocrinology

Article Title: Cell division cycle 20 promotes tumor progression and predicts poor clinical outcome in childhood and adult adrenocortical carcinoma ☆

doi: 10.1016/j.jcte.2025.100406

Figure Lengend Snippet: Identification of core gene CDC20 in ACC. (A) By integrating DEGs, genes with AUC values > 0.7, HR > 1, and P-values < 0.05 in the GSE10927 -19750 dataset, and genes with AUC values > 0.7, HR > 1, and P-values < 0.05 in TCGA datasets for overall survival (OS), progression-free interval (PFI), we identified 8 core genes. (B) Univariate Cox regression analysis of the 8 core genes across all cohorts. (C) AUC values of the 8 core genes across all cohorts. (D) Expression levels of CDC20 between ACC and normal tissues in GSE10927 , GSE19750 , and GSE10927 -19750 cohorts. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Article Snippet: The anti-CDC20 antibody (YT0791, Immunoway) was utilized for this IHC.

Techniques: Expressing

Journal: Journal of Clinical & Translational Endocrinology

Article Title: Cell division cycle 20 promotes tumor progression and predicts poor clinical outcome in childhood and adult adrenocortical carcinoma ☆

doi: 10.1016/j.jcte.2025.100406

Figure Lengend Snippet: Validation of CDC20 as an independent prognostic factor for ACC. (A–H) Kaplan-Meier survival analysis of CDC20 across all cohorts. (I) Univariate Cox regression analysis of CDC20, age, gender, and tumor stage across all cohorts. (J) Multivariate Cox regression analysis of CDC20 across all cohorts.

Article Snippet: The anti-CDC20 antibody (YT0791, Immunoway) was utilized for this IHC.

Techniques: Biomarker Discovery

Journal: Journal of Clinical & Translational Endocrinology

Article Title: Cell division cycle 20 promotes tumor progression and predicts poor clinical outcome in childhood and adult adrenocortical carcinoma ☆

doi: 10.1016/j.jcte.2025.100406

Figure Lengend Snippet: The gene set enrichment analysis (GSEA) results for the TCGA and GSE76019 datasets. (A) GSEA results of CDC20-related GO terms in TCGA dataset. (B) GSEA results of CDC20-related GO terms in GSE76019 dataset.

Article Snippet: The anti-CDC20 antibody (YT0791, Immunoway) was utilized for this IHC.

Techniques:

Journal: Journal of Clinical & Translational Endocrinology

Article Title: Cell division cycle 20 promotes tumor progression and predicts poor clinical outcome in childhood and adult adrenocortical carcinoma ☆

doi: 10.1016/j.jcte.2025.100406

Figure Lengend Snippet: Immunohistochemistry (IHC) staining results of CDC20 in ACC and adrenocortical adenoma. (A–C) Microscopic images (10×, 20×, 40×) of CDC20 IHC staining in adrenocortical adenoma. (D–F) Microscopic images (10×, 20×, 40×) of CDC20 IHC staining in ACC. (G) IHC scoring comparison between ACC (n = 6) and adrenocortical adenoma (n = 5) tissues.

Article Snippet: The anti-CDC20 antibody (YT0791, Immunoway) was utilized for this IHC.

Techniques: Immunohistochemistry, Comparison

Journal: Journal of Clinical & Translational Endocrinology

Article Title: Cell division cycle 20 promotes tumor progression and predicts poor clinical outcome in childhood and adult adrenocortical carcinoma ☆

doi: 10.1016/j.jcte.2025.100406

Figure Lengend Snippet: Cell experiments. (A) Western blotting to assess the impact of 3 siRNAs on CDC20 expression in ACC cells. (B–C) Quantitative analysis of CDC20 expression after CDC20 gene knockdown in NCI-H295R (B) and SW-13 (C) cell lines. (D) Colony formation assay results in NCI-H295R and SW-13 cell lines. (E–F) Quantification of proliferating cells in NCI-H295R (E) and SW-13 (F) cell lines. (G) Transwell assay results in NCI-H295R and SW-13 cell lines. (H–I) Quantification of migrating cells in NCI-H295R (H) and SW-13 (I) cell lines. *P < 0.05, **P < 0.01, ***P < 0.001, ns indicates no statistical significance.

Article Snippet: The anti-CDC20 antibody (YT0791, Immunoway) was utilized for this IHC.

Techniques: Western Blot, Expressing, Knockdown, Colony Assay, Transwell Assay

Journal: Journal of Clinical & Translational Endocrinology

Article Title: Cell division cycle 20 promotes tumor progression and predicts poor clinical outcome in childhood and adult adrenocortical carcinoma ☆

doi: 10.1016/j.jcte.2025.100406

Figure Lengend Snippet: Immune infiltration and immunotherapy. (A–D) Correlation analysis between CDC20 expression and CD8+ T cell infiltration levels using TIMER and Xcell algorithms in TCGA and GSE76019 datasets. (E–F) Assessment of tumor immune dysfunction and exclusion (TIDE) score correlation with CDC20 expression levels in TCGA and GSE76019 datasets. (G–H) Subclass mapping (Submap) algorithm evaluation of expression similarity between two CDC20 expression subgroups and different immunotherapy response patients in TCGA and GSE76019 datasets. (I–L) Kaplan-Meier survival analysis of high and low CDC20 expression subgroups among patients receiving anti-PD-1 therapy in four cohorts.

Article Snippet: The anti-CDC20 antibody (YT0791, Immunoway) was utilized for this IHC.

Techniques: Expressing

Journal: Journal of Clinical & Translational Endocrinology

Article Title: Cell division cycle 20 promotes tumor progression and predicts poor clinical outcome in childhood and adult adrenocortical carcinoma ☆

doi: 10.1016/j.jcte.2025.100406

Figure Lengend Snippet: Analysis of CDC20-related mutation and copy number variation (CNV). (A) Landscape of top 20 frequent mutated genes. (B) Differential expression of CDC20 between wild-type and mutated groups among the top 20 frequent mutated genes. (C) Landscape of top 10 chromosomal amplifications and top 10 chromosomal deletions. (D) Differential expression of CDC20 between variant and non-variant groups among the 10 chromosomal amplifications and top 10 chromosomal deletions. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns indicates no statistical significance.

Article Snippet: The anti-CDC20 antibody (YT0791, Immunoway) was utilized for this IHC.

Techniques: Mutagenesis, Quantitative Proteomics, Variant Assay